4.請說明健康食品雙軌審查制度，並依審查制度分別列舉一項產品說明其如何取得健康食品認證標章。（10%)

詳解 (共 1 筆)

丸

詳解 #3716835

2019/12/19

（一）第一軌：個案審查申請此類審查...

(共 1085 字，隱藏中）

前往觀看

Cardiovascular disease (CVD) and non-alcoholic fatty liver disease (NAFLD) are manifestations^ of the metabolic syndrome. CVD remains the number one cause of mortality in the West, while NAFLD is the most common liver disease. Growing evidence suggests that polyunsaturated fatty acids (PUFA) influence risk factors including circulating lipids and inflammation on the development of CVD and NAFLD. N~ 6 and n~3 PUFA are comprised of distinct family members, which are increasingly recognized for their individual effects. Therefore, this review examines what is currently known about the specific effects of the major n~3 and n - 6 PUFA on CVD and NAFLD. Overall, this review supports a beneficial effect of n - 3 PUFA and highlights distinctive effects between alpha-linolenic acid found in plant oils relative to marine derived eicosapentaenoic acid and docosahexaenoic acid. This review also highlights contrasting health effects between the n - 6 PUFA, linoleic and arachidonic acid.

4.請說明健康食品雙軌審查制度，並依審查制度分別列舉一項產品說明其如何取得健康食品認證標章。（10%)

詳解 (共 1 筆)

相關申論題

相關試卷

4.請說明健康食品雙軌審查制度，並依審查制度分別列舉一項產品說明其如何取得 健康食品認證標章。（10%)

詳解 (共 1 筆)

相關申論題

相關試卷

4.請說明健康食品雙軌審查制度，並依審查制度分別列舉一項產品說明其如何取得健康食品認證標章。（10%)